Nabriva Therapeutics - NBRV Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" NBRV shares.
View NBRV analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month price objectives for Nabriva Therapeutics' shares. Their NBRV share price forecasts range from $50.00 to $50.00. On average, they expect the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 2,662.4% from the stock's current price.
View analysts price targets for NBRV or view top-rated stocks among Wall Street analysts.

Nabriva Therapeutics' stock was trading at $1.89 at the start of the year. Since then, NBRV stock has decreased by 4.2% and is now trading at $1.81.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our NBRV earnings forecast.

Nabriva Therapeutics plc (NASDAQ:NBRV) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share for the quarter, topping analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 120.02% and a negative net margin of 133.25%.
Read the conference call transcript.

Shares of Nabriva Therapeutics reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Nabriva Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Charles A Rowland Jr, Colin Md Broom, J Christopher Naftzger, Stephen W Webster, Theodore R Schroeder and Theodore R Schroeder.
View institutional ownership trends.

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBRV stock can currently be purchased for approximately $1.81.

Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $55.46 million and generates $28.90 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($19.71) on an earnings per share basis.

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639.